BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, March 15, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 29, 2008
View Archived Issues
Clinical benefit and recommended dose found in phase II TAS-108 study in breast cancer patients
Read More
Korea Research Institute of Chemical Technology patents agents for cerebral ischemia, etc.
Read More
New antiinfective agents reported in recent patent literature
Read More
Merck Frosst patents novel renin inhibitors for cardiovascular disorders
Read More
Phase III study shows Rituxan decreases progression of joint damage in early RA
Read More
Biofrontera reports positive phase III results with BF-200 ALA in actinic keratosis
Read More
FDA grants orphan drug designation to TransMolecular's 131I-TM-601 for melanoma
Read More
ArQule signs definitive license agreement with Daiichi Sankyo for selective c-Met inhibitor ARQ-197
Read More
Novozymes grants sanofi-aventis worldwide license for antimicrobial peptide Plectasin NZ-2114
Read More
Newron receives approval to initiate European and Asian phase IIb/III study of ralfinamide in NLBP
Read More
Takeda receives Japanese approval for additional indication of Actos in type 2 diabetes
Read More
PAION and Ergomed complete phase IIa study of CNS-5161 in opioid-refractory cancer pain
Read More
FDA accepts for review NeurogesX's NDA for NGX-4010 in post-herpetic neuralgia
Read More
RegeneRx gives update on release of clinical trial information
Read More
GSK and Theravance present positive phase IIb results for GW-642444 in COPD
Read More
Forest and Pierre Fabre sign collaboration agreement for F-2695 in the U.S. and Canada
Read More
Memory Pharmaceuticals reports positive phase I data for R-4996/MEM-63908
Read More
CHMP recommends marketing authorization for Pfizer's Fablyn in osteoporosis
Read More
Novel peptide with antiinflammatory and cardioprotective activity discovered by Compugen
Read More
Inhibition of PDE4B receptor as a novel approach for the treatment of schizophrenia
Read More
SuperGen reports preclinical data for its panel of novel drugs for cancer
Read More
CHMP recommends new indication for Nycomed's TachoSil
Read More
CHMP recommends orphan drug status for Immunomedics' radiolabeled hPAM4
Read More
Takeda commences phase III cetilistat program in Japan for obesity
Read More
ArQule presents update on development of ARQ-621 and ARQ-761
Read More
FDA grants marketing authorization to Antisoma's oral fludarabine phosphate in CLL
Read More
